Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study
Clinical Obesity · 2025-02 · 15 (1)
DOI: 10.1111/cob.12704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Obesity, online erschienen am 28.10.2024. Verfasst von Carel W Le Roux und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Complications Research Centre, School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dubl…. Hauptthemen laut MEDLINE: Obesity, Health Personnel. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
A cross‐sectional, online survey was conducted in the United Kingdom, France, Germany, and the United States (14 November–22 December 2022) to investigate preferences for anti‐obesity medication (AOM) among people with obesity (PwO) and healthcare providers (HCPs). Eligibility: Adult PwO who self‐defined their body type as overweight/obese, were trying to lose weight and had BMI ≥30.0 or 27.0–29.9 kg/m 2 with ≥1 obesity‐related complication; HCPs had to see ≥30 PwO in a typical month and be a decision‐maker regarding their weight loss. The survey included 2500 PwO and 500 HCPs. Exercise (96%) and diet (90%) were the most common weight management methods; AOM use was low (8%). Key barriers to use of prescribed AOMs among PwO were not wanting to take AOM (34%), side effects concerns (33%), and not trusting AOM (26%). Most HCPs (79%) had prescribed/recommended AOMs. Efficacy was the most common reason for preferring one of the shown product profiles among PwO (60%) and HCPs (86%); improving cardiovascular risk was also important to 95% of HCPs when deciding which AOM to prescribe. AOM preference is largely driven by efficacy. Increasing knowledge could help to address barriers to AOM use and improve outcomes for PwO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Complications Research Centre, School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
- Market Access, Novo Nordisk, Novo Nordisk A/S, Søborg, Denmark.
- Market Access, Novo Nordisk, Ipsos, London, UK.
Förderung
- Novo Nordisk
Zitieren
APA
Le Roux, C. W., Koroleva, A., Larsen, S., & Foot, E. (2025). Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study. Clinical Obesity, 15(1). https://doi.org/10.1111/cob.12704
Vancouver
Le Roux CW, Koroleva A, Larsen S, Foot E. Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study. Clinical Obesity. 2025;15(1). doi:10.1111/cob.12704
BibTeX
@article{LeRoux2025,
author = {Le Roux, Carel W and Koroleva, Anna and Larsen, Sara and Foot, Ellie},
title = {Anti‐obesity treatment preferences of healthcare providers and people living with obesity: A survey‐based study},
journal = {Clinical Obesity},
year = {2025},
volume = {15},
number = {1},
doi = {10.1111/cob.12704}
}
EUVIMED